New cancer drug GEN1056 tested in humans for first time

NCT ID NCT05586321

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This early-stage trial tested a new drug called GEN1056 in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for any signs that the drug might shrink tumors, but this was a small, first-in-human study focused on safety, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, Georgia

  • ARENSIA Exploratory Medicine Phase I Unit

    Chisinau, Moldova

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • MD Anderson Cancer Centre

    Madrid, Spain

Conditions

Explore the condition pages connected to this study.